Chan, Iris T.
Genentech
4 papers on CoChatORCID 0000-0001-9555-8522
Most cited papers
- Verified
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., et al. (2016) · Nature Communications
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 309
- Verified
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease
Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D. A., Jacks, T., et al. (2004) · Journal of Clinical Investigation
Acute Myeloid Leukemia ResearchProtein Tyrosine Phosphatases
Cited by 270
- Verified
Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)
Flygare, J. A., Beresini, M., Budha, N., Chan, H., Chan, I. T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S. G., et al. (2012) · Journal of Medicinal Chemistry
Cell death mechanisms and regulationHeterocyclic Compound Synthesis and Bioactivity
Cited by 252
- Verified
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Shapiro, G. I., LoRusso, P., Kwak, E., Pandya, S., Rudin, C. M., Kurkjian, C., Cleary, J. M., Pilat, M. J., Jones, S., de Crespigny, A., et al. (2020) · Investigational New Drugs
PI3K/AKT/mTOR signaling in cancerMelanoma and MAPK Pathways
Cited by 90
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free